Related Experiment Video
Updated: Jul 18, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated
David P Steensma1, Jonathan S C Caudill, Animesh Pardanani
1Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Steensma.david@mayo.edu
Haematologica
|December 30, 2006
Abstract:
Discovery of a constitutively activating point mutation of the Janus kinase 2 (JAK2) receptor-associated tyrosine kinase in patients with polycythemia vera (PV) and other BCR/ABL-negative myeloproliferative disorders prompted many groups around the world to examine diverse subsets of patients with myeloid diseases for the prevalence of the JAK2 V617F mutation and its clinical and pathological associations.
